美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

TransAtlantic Petroleum Ltd

0.2460

0.0000

成交量：- -

成交额：- -

市值：1,869.66万

市盈率：-0.46

高：0.2460

开：0.2460

低：0.2460

收：0.2460

52周最高：0.8400

52周最低：0.1200

股本：7,600.26万

流通股本：3,946.96万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.5370

每股收益(LYR):-0.0973

净资产收益率：-90.35%

总资产收益率：-7.65%

市净率：-0.96

市盈率(LYR):-2.53

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

破伤风抗毒素“隐形冠军”江西生物再冲港股：频繁股权代持遭遇证监会问询，营收高度依赖单一产品

江西生物IPO：单一产品依赖症明显“第二曲线”遥遥无期历史沿革疑云密布递表前大额分红

江西生物IPO：新一代TAT与资本动作共振，抗血清龙头的价值突围之路

新股消息 | 江西生物再次递表港交所公司为中国及全球最大的人用TAT提供商

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/TAT"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TAT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TAT\",,,,,undefined,":{"symbol":"TAT","market":"US","secType":"STK","nameCN":"TransAtlantic Petroleum Ltd","latestPrice":0.246,"timestamp":1654891200000,"preClose":0.246,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":39469571,"shares":76002557,"eps":-0.53704,"marketStatus":"未开盘","change":0,"latestTime":"06-10 16:00:00 EDT","open":0.246,"high":0.246,"low":0.246,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.53704,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1260248400000,"exchange":"AMEX","adjPreClose":0.246,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TAT\",,,,,undefined,":{"symbol":"TAT","floatShares":39469571,"roa":"-7.65%","roe":"-90.35%","lyrEps":-0.097326,"shares":76002557,"dividePrice":0,"high":0.246,"amplitude":0,"preClose":0.246,"low":0.246,"week52Low":0.12,"pbRate":"-0.96","week52High":0.84,"institutionHeld":0.084,"latestPrice":0.246,"eps":-0.53704,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.53704,"open":0.246,"prevYearClose":0.4883},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TAT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-12-18","symbol":"TAT","reason":null,"defaultRemindTime":1608301800000,"announcedDate":"2020-12-15","type":"delisting","dateTimestamp":1608267600000},{"date":"2020-08-12","symbol":"TAT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1597262400000,"name":null,"time":"盘后","dateTimestamp":1597204800000,"actualEps":null},{"date":"2020-06-17","symbol":"TAT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1592424000000,"name":null,"time":"盘后","dateTimestamp":1592366400000,"actualEps":null},{"date":"2020-03-25","symbol":"TAT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1585166400000,"name":null,"time":"盘后","dateTimestamp":1585108800000,"actualEps":null},{"date":"2019-11-12","symbol":"TAT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1573592400000,"name":null,"time":"盘后","dateTimestamp":1573534800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TAT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TAT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TAT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TAT","date":"2020-12-16","current":-0.458066,"percent":0.659761,"low":-69.640654,"twenty":-4.364988,"median":-1.901598,"eighty":-0.296655,"high":9.945011,"avg":-4.27987,"sd":12.072841,"marketCap":19540257},"quantilePoints":[],"updateTime":1770708518443},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TAT\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586872449","title":"破伤风抗毒素“隐形冠军”江西生物再冲港股：频繁股权代持遭遇证监会问询，营收高度依赖单一产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2586872449","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586872449?lang=zh_cn&edition=fundamental","pubTime":"2025-11-25 13:36","pubTimestamp":1764049016,"startTime":"0","endTime":"0","summary":"作为国内破伤风抗毒素领域的“隐形冠军”，江西生物超90%收入来自人用破伤风抗毒素，引发业内关注。频繁股权代持遭遇证监会问询招股书显示，目前掌舵江西生物的是一位“90后”。现年32岁的敬玥2017年5月加入江西生物，2022年1月起担任董事长。除了历史股权代持情况遭遇证监会问询，值得注意的是，股权高度集中的江西生物在上市前出现“清仓式分红”。不过，该公司也被指过度依赖单一产品。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1764048924064767127","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["TAT"],"gpt_icon":0},{"id":"2583526419","title":"江西生物IPO：单一产品依赖症明显“第二曲线”遥遥无期 历史沿革疑云密布递表前大额分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2583526419","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583526419?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 13:39","pubTimestamp":1763098740,"startTime":"0","endTime":"0","summary":"　　近日，人用破伤风抗毒素提供商江西生物制品研究所股份有限公司向港交所递交IPO申请，拟于港交所主板挂牌上市。　　招股书显示，凭借人用破伤风抗毒素，公司业绩近年实现快速增长，2022年至2024年总收入从1.42亿元增长至2.21亿元，复合年增长率达24.7%；同期利润从2646.8万元提升至7514万元，复合年增长率高达68.5%。然而，在亮眼的业绩表现背后，过度依赖单一产品、错综复杂的股权关系等问题，为其上市之路增添了诸多不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-11-14/doc-infxkapa3028873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TAT"],"gpt_icon":0},{"id":"2582245383","title":"江西生物IPO：新一代TAT与资本动作共振，抗血清龙头的价值突围之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2582245383","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582245383?lang=zh_cn&edition=fundamental","pubTime":"2025-11-12 17:44","pubTimestamp":1762940695,"startTime":"0","endTime":"0","summary":"近日，江西生物推出新一代破伤风抗毒素（TAT），凭借三大独有技术突破，成功重塑破伤风抗毒素领域的行业标准。","market":"hk","thumbnail":"https://img7.gelonghui.com/column/9.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/9.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3183913","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["TAT"],"gpt_icon":0},{"id":"2578637155","title":"新股消息 | 江西生物再次递表港交所 公司为中国及全球最大的人用TAT提供商","url":"https://stock-news.laohu8.com/highlight/detail?id=2578637155","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578637155?lang=zh_cn&edition=fundamental","pubTime":"2025-10-26 20:45","pubTimestamp":1761482738,"startTime":"0","endTime":"0","summary":"据招股书披露，江西生物是中国最大的人用破伤风抗毒素提供商和出口商，也是全产业链贯通的抗血清平台商。资料显示，江西生物已建立人用药和兽药的协同产品组合。根据弗若斯特沙利文的资料，江西生物是中国及全球最大的人用TAT提供商，按2024年销量计，市场份额分别为65.8%及36.6%。根据弗若斯特沙利文的资料，公司于中国人用TAT市场一直占据主导地位，市场份额连续18年保持50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","TAT"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TAT\",params:#limit:6,delay:false,,,undefined,":[]}}